After Hours Gainer
AURA Aura Biosciences10.29+0.04+0.4%
After Hours:11.00+0.71 (+6.9%)
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Globe NewswireThu, 17-Oct 4:05 PM
Premarket Decliner
AURA Aura Biosciences11.00-0.98-8.2%
Premarket:8.41-2.59 (-23.6%)
Aura Biosciences Announces Pricing of Public Offering of Common Stock
Business WireMon, 6-Nov 10:02 PM
